InVivo Therapeutics Holdings Corp.
11
Mary F. Walrath
02/01/2024
02/15/2024
Yes
v
JNTADMN, CLMSAGNT |
Assigned to: Mary F. Walrath Chapter 11 Voluntary Asset |
|
Debtor InVivo Therapeutics Holdings Corp., Debtor
1500 District Avenue Burlington, MA 01803 MIDDLESEX-MA Tax ID / EIN: 36-4528166 |
represented by |
Matthew B. McGuire
Landis Rath & Cobb LLP P.O. Box 2087 919 Market Street, Suite 1800 Wilmington, DE 19899 302-467-4400 Fax : 302-467-4450 Email: mcguire@lrclaw.com |
U.S. Trustee U.S. Trustee
Office of the United States Trustee J. Caleb Boggs Federal Building 844 King Street, Suite 2207 Lockbox 35 Wilmington, DE 19801 (302)-573-6491 |
| |
Claims Agent Kurtzman Carson Consultants LLC
www.kccllc.net 222 N. Pacific Coast Highway Suite 300 El Segundo, CA 90245 310-823-9000 |
Date Filed | # | Docket Text |
---|---|---|
02/15/2024 | 5 | Schedules/Statements filed: , Stmt of Financial Affairs,. Filed by InVivo Therapeutics Holdings Corp.. (McGuire, Matthew) (Entered: 02/15/2024) |
02/15/2024 | 4 | Schedules/Statements filed: Sch A-B, Sch D, Sch E-F, Sch G, Sch H, , Sum of Assets and Liabilities, Decl Concerning Debtors Schs,. Filed by InVivo Therapeutics Holdings Corp.. (McGuire, Matthew) (Entered: 02/15/2024) |
02/06/2024 | 3 | Order Authorizing Joint Administration An order has been entered in this case directing the procedural consolidation and joint administration of the chapter 11 cases of Invivo Therapeutics Corporation and its affiliate. The docket in the chapter 11 case of InVivo Therapeutics Corporation, Case No. 24- 10137 (MFW) should be consulted for all matters affecting this case. Signed on 2/6/2024 (LAM) Modified on 2/7/2024 (JMC). (Entered: 02/06/2024) |
02/01/2024 | Judge Mary F. Walrath added to case (SH) (Entered: 02/01/2024) | |
02/01/2024 | 2 | Receipt of filing fee for Voluntary Petition (Chapter 11)( 24-10138) [misc,volp11a] (1738.00). Receipt Number A11438976, amount $1738.00. (U.S. Treasury) (Entered: 02/01/2024) |
02/01/2024 | 1 | Chapter 11 Voluntary Petition . Fee Amount $1738. Filed by InVivo Therapeutics Holdings Corp.. (McGuire, Matthew) (Entered: 02/01/2024) |